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Abstract Measurements of serum prostate-speciﬁc anti-
gen (PSA) protein levels form the basis for a widely used
test to screen men for prostate cancer. Germline variants in
the gene that encodes the PSA protein (KLK3) have been
shown to be associated with both serum PSA levels and
prostate cancer. Based on a resequencing analysis of a
56 kb region on chromosome 19q13.33, centered on the
KLK3 gene, we ﬁne mapped this locus by genotyping tag
SNPs in 3,522 prostate cancer cases and 3,338 controls
from ﬁve case–control studies. We did not observe a strong
association with the KLK3 variant, reported in previous
studies to confer risk for prostate cancer (rs2735839;
P = 0.20) but did observe three highly correlated SNPs
(rs17632542, rs62113212 and rs62113214) associated with
prostate cancer [P = 3.41 9 10
-4, per-allele trend odds
ratio (OR) = 0.77, 95% CI = 0.67–0.89]. The signal was
apparent only for nonaggressive prostate cancer cases with
Gleason score \7 and disease stage \III (P = 4.72 9
10
-5, per-allele trend OR = 0.68, 95% CI = 0.57–0.82)
and not for advanced cases with Gleason score[8 or stage
CIII (P = 0.31, per-allele trend OR = 1.12, 95% CI =
0.90–1.40). One of the three highly correlated SNPs,
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change in the KLK3 protein with a predicted benign or
neutral functional impact. Baseline PSA levels were 43.7%
higher in control subjects with no minor alleles (1.61 ng/
ml, 95% CI = 1.49–1.72) than in those with one or more
minor alleles at any one of the three SNPs (1.12 ng/ml,
95% CI = 0.96–1.28) (P = 9.70 9 10
-5). Together our
results suggest that germline KLK3 variants could inﬂuence
the diagnosis of nonaggressive prostate cancer by inﬂu-
encing the likelihood of biopsy.
Introduction
Prostate cancer is the most commonly diagnosed non-
cutaneous cancer in men in the United States with over
200,000 new cases and 30,000 deaths estimated in 2010
(Jemal et al. 2010). Over 35 prostate cancer risk loci have
been reported to date from a series of genome-wide asso-
ciation studies (GWAS). One locus maps to a region on
chromosome 19q13.33 marked by SNP rs2735839, located
*600 bp downstream of KLK3, the gene that encodes
prostate-speciﬁc antigen (PSA).
This locus was initially reported in a GWAS of prostate
cancer conducted in subjects from the UK and Australia
(with a P value of 1.5 9 10
-18) (Eeles et al. 2008). Other
prostate cancer GWAS efforts, including the Cancer
Genetic Markers of Susceptibility (CGEMS) project in the
US, did not report a GWAS signiﬁcant association between
SNPs on chromosome 19q13.33 and prostate cancer risk
(Gudmundsson et al. 2009; Sun et al. 2009; Thomas et al.
2008). An important difference in study design could
account for the divergent results in the GWAS: in the study
that reported the prostate cancer association for the KLK3
locus, controls were selected to have low PSA levels
(\0.5 ng/ml) (Eeles et al. 2008) whereas the other studies
did not select controls based on PSA levels. In a follow-up
analysis of the UK GWAS, the signal was observed
although not as strongly as in the discovery data set
(Kote-Jarai et al. 2008). In a subsequent re-analysis of the
CGEMS GWAS (within the Prostate, Lung, Colon Ovarian
screening trial, PLCO) an association between rs2735839
and prostate cancer risk was seen only when control indi-
viduals were restricted to those with very low PSA levels
(Ahn et al. 2008).
In a previous study, we catalogued common SNPs and
insertion/deletion polymorphisms (indels) in the KLK3
region by a resequence analysis of a 56 kb region ﬂanking
rs2735839 (chr19:56,019,829–56,076,043 bps; NCBI
Build 36.3) in 78 unrelated individuals of European
ancestry (Parikh et al. 2010). Based on these results, we
tagged the genomic region surrounding rs2735839 and
genotyped 24 SNPs in ﬁve prostate cancer case–control
studies from the United States, France, Norway and Fin-
land (1994; Calle et al. 2002; Naess et al. 2008; Prorok
et al. 2000; Valeri et al. 2003).
In our analysis, we did not observe a signiﬁcant asso-
ciation between rs2735839 and prostate cancer risk, but
found suggestive evidence for three highly correlated SNPs
in the KLK3 gene. Interestingly, the association with these
markers was observed only for nonaggressive prostate
cancer, deﬁned by a Gleason score lower than 7 and disease
stage\III, and not for cases with Gleason score 8 or greater
or Stage III and above (also known as advanced disease).
These three SNPs are also associated with baseline serum
PSA levels. Our results suggest that the observed associa-
tion between germline variation in the KLK3 gene and
nonaggressive prostate cancer, at least in part, may be
mediated by the association between the germline variation
and PSA levels.
Methods
Sample collections
This study included 3,522 prostate cancer cases and 3,338
control subjects from four case–control studies nested
within cohorts and one hospital based case–control study
(Supplemental Table 1), previously analyzed in the Cancer
Genetics Markers of Susceptibility (CGEMS) study. The
cohort studies were: the Prostate, Lung, Colon and Ovarian
(PLCO) Cancer Screening Trial (Gohagan et al. 2000;
Prorok et al. 2000), the Alpha-Tocopherol, Beta-Carotene
Cancer Prevention Study (ATBC) (1994), the American
Cancer Society Prevention Study II Nutrition Cohort (CPS-
II) (Calle et al. 2002) and the Cohort of Norway (CONOR)
(Naess et al. 2008). The case–control study was the French
Prostate Case–Control Study (CeRePP) (Valeri et al. 2003).
Details of the PLCO, ATBC, CPS-II, CONOR and CeRePP
have been previously described elsewhere in CGEMS
(Yeager et al. 2009). All studies were approved by the
appropriate institutional review boards.
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123SNP selection, pre-genotyping quality control (QC)
and genotyping
Pairwise analysis of linkage disequilibrium identiﬁed a set
of tagging single-nucleotide polymorphisms (SNPs) using
a criteria of a linkage disequilibrium coefﬁcient threshold
of r
2 C 0.8 and minor allele frequency (MAF) C0.05 based
on the resequencing data in the KLK3 region on
chr19:56,019,829–56,076,043 (NCBI Build 36.3) (Sup-
plemental Table 2) (Parikh et al. 2010) in the program
GLU (http://code.google.com/p/glu-genetics). Twelve tag
SNPs, covering an 8 kb region surrounding rs2735839,
were selected for genotyping. They capture 90% of com-
mon variation (MAF C0.05) across the 8 kb region sur-
rounding rs2735839 (r
2 C 0.8) based on the 1,000
Genomes Project data (overall 40 SNPs in the Caucasians
from Utah, USA (CEU) population samples, June 2010
release, http://www.1000genomes.org/). An additional 12
SNPs with r
2[0.3 with rs2735839 were also included.
The program, Tagger, was used to estimate the proportion
of common variation across the region captured by the tag
SNPs based on a multi-marker tagging approach (de Bak-
ker et al. 2005). The 24 SNPs (Fig. 1; Supplemental
Table 3) extend across the entire KLK3 gene and in addi-
tion cover 12,907 bps upstream and 3,424 bps downstream
of the gene (Parikh et al. 2010).
After pre-genotyping quality control at the Core Geno-
typing Facility (CGF) of the National Cancer Institute
(http://cgf.nci.nih.gov/operations/pregenotyping-qaqc.html),
24 SNPs were genotyped in 8,505 samples using TaqMan
genotyping assays (ABI, Foster City, CA, USA). For
quality control assessment, 5.2–6.1% of samples from each
of the ﬁve studies were genotyped in duplicate (a total of
466 samples) with 98.1% genotype concordance overall.
When 13 duplicate pairs with low completion rates (\80%)
were excluded, the concordance for the remaining 453
duplicate sample increased to 99.6%. One SNP, rs2735839,
had previously been genotyped as part of CGEMS for all
studies except CONOR. Genotypes for this SNP were
retrieved from CGEMS for subjects in PLCO, ATBC, CPS-
II and CeRePP and combined with other genotypes before
analysis.
Post-genotyping quality control
As per the standard CGF protocol, samples with \80%
completion were excluded (n = 612), which increased the
overall completion rate to[98% in the combined data set
and the locus completion rate to[90%. An additional 90
subjects with \80% estimated CEU admixture were
excluded, as well as 159 participants that did not meet
eligibility requirements (Supplemental Table 4) based on
prior GWAS and dense SNP genotyping (Yeager et al.
2007, 2009). Deviations from Hardy–Weinberg equili-
brium (HWE) were tested using an exact test in the control
group of each cohort. Signiﬁcant deviation from HWE
(P\1 9 10
-4) was observed for one SNP (CGF_34700)
that was subsequently excluded in further analysis. A ﬁnal
genotype data set from 6,860 subjects for 23 SNPs was
analyzed. A two group v
2 test of equal proportions (New-
combe 1998) was performed to determine the differences
in MAFs for each of the 23 SNPs analyzed in this study and
the CEU population available in the 1,000 Genomes Pro-
ject data (June 2010 release, http://www.1000genomes.org/).
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Fig. 1 a Genomic structure of
the KLK3 region indicating the
location of the 24 SNPs geno-
typed. SNPs that associate with
prostate cancerand/orPSA levels
are colored in black (nonag-
gressive prostate cancer and PSA
levels) and in red (only PSA
levels). Locations of other SNPs
areindicatedbyarrows.OneSNP
that was excluded from analysis
based on deviation from Hardy–
Weinberg equilibrium is shown
with a gray arrow.T h eb o u n d a r y
oftheKLK3geneisindicatedwith
a horizontal arrow. Exons are
indicatedbyboxesandintronsare
by solid lines. b Linkage
disequilibrium (LD) map for the
24 genotyped SNPs in KLK3.
Each diamond represents the
correlationcoefﬁcientr
2,between
every pair of SNPs. Darker
shades represent stronger LD
Hum Genet (2011) 129:675–685 677
123Power was estimated using Quanto under the log-additive
model at a = 0.05 [http://hydra.usc.edu/gxe/ (Gauderman
2002)]. This study had[80% power to detect an associa-
tion with an odds ratio of 1.25 (assuming a MAF of 0.05, a
prevalence of prostate cancer of 1.5067% and alpha of
0.05) (http://seer.cancer.gov/csr/1975_2007/).
Statistical analysis
Single locus case–control association analysis was per-
formed using the programs, GLU and PLINK. In order
to incorporate prostate cancer stage and grade at diagno-
sis, we discriminated between nonaggressive (Gleason
score \7 AND disease stage \III, n = 1,654), advanced
prostate cancer (Gleason score C8 OR disease stage CIII,
n = 678) or aggressive prostate cancer (Gleason score C7
OR disease stage CIII, n = 1,475) as deﬁned in CGEMS
(Thomas et al. 2008; Yeager et al. 2007). Logistic regres-
sion models were adjusted for study (ATBC, CPS-II,
CeRePP, PLCO and CONOR), arm (for CeRePP and
PLCO), age (in 10-year categories) and two principal
components of population structure as identiﬁed in the
PLCO study (as these two principal components were
signiﬁcant predictors of the disease status identiﬁed under
null logistic model). Both a two degree of freedom (df)
genotype effect model and 1 df trend effect model were
tested. We found no evidence of heterogeneity in genetic
effects across study using the Q and I
2 statistics.
We analyzed the association between SNPs in KLK3 and
serum PSA levels in 702 control subjects and 461 incident
prostate cancer cases from the PLCO cohort. PSA mea-
surements at baseline (the ﬁrst PSA test performed as men
entered the PLCO Cancer Screening Trial) were available
for this study (Thomas et al. 2008; Ahn et al. 2008). We
excluded men diagnosed with prostate cancer in their ﬁrst
year of the PLCO trial (n = 217) as many present with
extremely high PSA levels probably due to more advanced
disease as compared to men diagnosed later in the trial
(range: 0.32–617.80 ng/ml, average 19.11 ng/ml) and con-
trol subjects with missing PSA level information (n = 20).
The average time between baseline PSA and diagnosis for
the cases included in this study was 2.5 years (median
2.0 years). Average PSA levels were 1.53 ng/ml (median
1.11) in control subjects; 8.94 ng/ml (median 4.12) in all
cases; and 4.23 ng/ml (median 3.43) in cases diagnosed
after the ﬁrst year of the PLCO trial. For each desired SNP,
we deﬁned a group of individuals without a minor allele
(G = 0) and with at least one minor allele (G = 1) and
estimated the mean baseline PSA in these two groups. To
minimize the inﬂuence of the larger values, we also created
a truncated PSA level for control subjects (at 4 ng/ml) and
cases (at 8 ng/ml) and performed a similar analysis. For a
formal statistical test, we compared PSA and genotype (G),
using a general linear model with a gamma distribution and
aloglinkfunction.Theresultswereessentiallyequivalentto
those obtained by performing a linear model on the log-
transformed PSA level. We adjusted for center, age group
andpopulationstratiﬁcation.Onlyoneprincipalcomponent,
estimated to adjust for population structure, was a signiﬁ-
cant predictor of PSA level under null linear model based on
prior analyses in CGEMS (Yeager et al. 2007).
Imputation
We imputed genotypes for an approximately 56 kb region on
chromosome 19q33.13 (chr19:56,019,829–56,076,043 bps;
NCBI Build 36.3) for 2,303 samples (1,179 cases and 1,124
control subjects) from the PLCO Cancer Screening Trial
using IMPUTEv2 (Howie et al. 2009). The PLCO subjects
were genotyped as part of the CGEMS prostate cancer
whole-genome scan (Phase 1A with Illumina Human-
Hap300 and Phase 1B with Illumina HumanHap240 assays,
Illumina Corp., San Diego, CA, USA) (Thomas et al. 2008;
Yeager et al. 2007). Other studies that were part of this work
did not have whole-genome SNP data and were not used for
imputation. We used 120 estimated CEU haplotypes from
the June 2010 release of the 1,000 Genomes Pilot 1 data
(Durbin et al. 2010) as well as 298 estimated CEU and
Tuscans in Italy (TSI) haplotypes from the HapMap3 pro-
ject to carry out genotype imputation (Altshuler et al. 2010).
Association analysis was conducted using SNPTESTv2
(Marchini et al. 2007) with logistic regression models (1 df
trend test) adjusted for age (in 10-year categories) and two
principal components of genetic structure as identiﬁed in
the PLCO study (Yeager et al. 2007).
Bioinformatic analysis of a KLK3 coding variant
Four computational tools were used to assess the predictive
value of a non-synonymous substitution caused by
rs17632542 on the KLK3 protein. Polyphen-2 (Polymor-
phism Phenotyping) (Ramensky et al. 2002), SIFT (Sorting
Intolerant From Tolerant) (Ng and Henikoff 2001),
SNPs&GO (SNPs and Gene Ontology) (Calabrese et al.
2009) and Prophyler (Protein Phylogeny and Evolutionary
Rates) (Binkley et al. 2010) predict functionally relevant
disease-related mutations based on one or more of the
following: sequence conservation, steric and biochemical
properties of amino acid residues and protein functional
annotation (SNPs&GO only).
Results
A total of 3,522 prostate cancer cases and 3,338 control
subjects from ﬁve case–control studies were analyzed in
678 Hum Genet (2011) 129:675–685
123the current study (Supplemental Table 1), including 1,654
men diagnosed with nonaggressive prostate cancer (Glea-
son score \7 and disease stage \III) and 678 men with
advanced prostate cancer (Gleason score C8 or stage CIII).
We also analyzed men with aggressive prostate cancer
(n = 1,475) by including cases with a Gleason score of 7
or higher (Gleason score C7 or stage CIII).
SNP selection and genotyping
Twenty-four SNPs in a 22 kb region surrounding
rs2735839, the initial marker found to be associated with
prostate cancer risk, were genotyped (physical locations
shown in Fig. 1a). Twelve of these SNPs were selected to
tag the genomic region of KLK3 at a linkage disequilibrium
(LD) coefﬁcient threshold of r
2 C 0.8 and a minor allele
frequency (MAF) C0.05. They capture 90% of common
variation (r
2 C 0.8 and MAF C0.05) across the 8 kb region
surrounding rs2735839 based on the 1,000 Genomes Pro-
ject data. An additional 12 SNPs with an r
2[0.3 with
rs2735839 were also genotyped to capture markers in both
modest and high LD with this SNP. One SNP was excluded
from further analysis because of substantial deviation from
Hardy–Weinberg equilibrium. No signiﬁcant differences
were observed between minor allele frequencies of SNPs in
control subjects of the current study and those of the CEU
population from the 1,000 Genomes Project (Supplemental
Table 3). The linkage disequilibrium structure across the
KLK3 locus in control subjects (Fig. 1b) reﬂects the rela-
tively low degree of LD seen in our resequence analysis
(Parikh et al. 2010).
Association of SNPs in KLK3 with prostate cancer
Four SNPs were associated with overall prostate cancer at a
signiﬁcance level of P\1 9 10
-3 (Table 1). The most
signiﬁcant association was with rs17632542 (P = 3.41 9
10
-4, per-allele trend OR 0.77, 95% CI 0.67–0.89;
unconstrained heterozygote OR (ORhet) 0.80, 95% CI
0.69–0.93 and homozygote OR (ORhom) 0.37, 95% CI
0.16–0.86). Two additional SNPs, both highly correlated to
rs17632542 (r
2 C 0.97), showed a similar level of signiﬁ-
cance: rs62113214 (P = 3.57 9 10
-4) and rs62113212
(P = 1.17 9 10
-3). No other SNPs were nominally sig-
niﬁcant after adjusting for any of the three SNPs (data not
shown). The marker initially reported to be associated with
prostate cancer risk in a GWAS (Eeles et al. 2008) was not
signiﬁcant in our study (rs2735839, P = 0.197).
When the analysis was stratiﬁed by disease severity, the
association was observed only with nonaggressive prostate
cancers (Gleason score\7 and disease stage\III) for the
three highly correlated SNPs (Table 2). SNP rs62113214
had the lowest P value (P = 4.72 9 10
-5, per-allele trend
OR 0.68, 95% CI 0.57–0.82; unconstrained heterozygote
OR (ORhet) 0.70, 95% CI 0.57–0.85 and homozygote OR
(ORhom) 0.34, 95% CI 0.11–1.04). The two highly
correlated SNPs rs17632542 (P = 5.49 9 10
-5) and
rs62113212 (P = 5.74 9 10
-5) showed similar results.
SNP rs2735839 was marginally associated with nonag-
gressive prostate cancer (P = 0.031). No SNPs were
associated with advanced prostate cancer (P[0.05) as
deﬁned by a Gleason score C8 or disease stage CIII
(Table 3) or with aggressive prostate cancer (P[0.05) as
deﬁned by a Gleason score C7 or stage CIII when com-
pared to control subjects (Supplemental Table 5). When
nonaggressive cases were compared to advanced cases a
signiﬁcant difference was seen for the same three SNPs
(rs62113212: P = 3.23 9 10
-5, per-allele trend OR 0.59,
95% CI 0.46–0.76) indicating that this signal could be
related to the less aggressive and often latent forms of
prostate cancer, which are diagnosed partly as a conse-
quence of PSA screening (Supplemental Table 6).
KLK3 SNPs and serum PSA levels
The PSA test is commonly used to screen for prostate
cancer and has been shown to increase detection of early,
nonaggressive prostate cancer. We assessed baseline PSA
levels according to different genotypes at the three highly
correlated SNPs: rs17632542, rs62113212 and rs62113214,
as well as at rs2735839. Because PSA information was
only available in the PLCO cohort, we performed the
analysis in this subset (702 control subjects and 461 cases).
Baseline PSA levels differed signiﬁcantly (Table 4)
between control individuals without or with one or more
minor alleles at any one of the three highly correlated
SNPs. Mean PSA levels were 1.61 ng/ml (95% CI
1.49–1.72) in men without a minor allele, and 1.12 ng/ml
(95% CI 0.96–1.28) in men with at least one minor allele at
rs62113212. The signiﬁcance of the differences was con-
ﬁrmed by a general linear model (P = 9.7 9 10
-5). The
box plot (Fig. 2a) shows that the entire distribution of PSA
levels was shifted to lower values in the group with the
minor allele (G = 1). Because of the high correlation with
rs62113212, the results for rs17632542 and rs62113214
were nearly identical (Table 4). After truncating PSA at
4 ng/ml in control subjects, to limit the inﬂuence of larger
values, we still found the mean PSA levels for the two
groups to be signiﬁcantly different [1.49 ng/ml (95% CI
1.41–1.58) vs. 1.11 ng/ml (95% CI 0.96–1.26), P = 1.5 9
10
-5 for rs62113212].
PSA levels were also lower in men carrying one or more
minor alleles at rs2735839 (1.28 ng/ml for carriers of at
least one minor allele compared to 1.64 ng/ml) as shown in
Table 4 and Fig. 2b. Although not statistically signiﬁcant,
cases with at least one minor allele at any of the four
Hum Genet (2011) 129:675–685 679
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123SNPs also had lower PSA levels than their respective
counterparts.
Genotype imputation
Imputation was performed in the PLCO GWAS data set
genotyped within the Cancer Genetic Markers of Sus-
ceptibility (CGEMS) study (Thomas et al. 2008; Yeager
et al. 2007) utilizing the publicly available HapMap and
1,000 genomes pilot project data sets (June 2010 release).
This added 239 imputed SNPs to the 27 SNPs already
genotyped as part of the CGEMS study (Thomas et al.
2008; Yeager et al. 2007) in the 56 kb region (chr19:
56,020,000–56,076,000) for a combined data set of 266
SNPs in 1,179 cases and 1,124 control subjects. We did
not observe a stronger association (P\1 9 10
-4) for
either prostate cancer overall or speciﬁcally for nonag-
gressive prostate cancer using imputed genotype data
(Supplemental Tables 7 and 8). However, the imputation
was performed in a subset of the cohorts (approximately
20% of subjects).
Prediction of functional effects of rs17632542
on KLK3
The three SNPs that most signiﬁcantly associated with
prostate cancer risk in our study: rs62113212, rs62113214
and rs17632542 are all located in the KLK3 gene (Fig. 1a).
The ﬁrst two are located in introns 2 and 4, respectively,
whereas rs17632542 lies within exon 4. The minor allele
(C) of rs17632542 causes a non-synonymous amino acid
change from isoleucine (hydrophobic) to threonine (polar)
at position 179 (Ile179Thr) in KLK3. This amino acid is
conserved in humans, chimpanzee and rhesus but not in
other mammals or vertebrates. The amino acid change
seems to have deleterious effects based on Sorting Into-
lerant from Tolerant (SIFT) analysis with a SIFT score of
0.03. A benign impact is predicted by Polyphen-2 and a
moderate impact is predicted by ProPhylER (multivariate
analysis of protein polymorphism (MAPP) P value of
0.0058). Finally, when taking functional annotation into
account (SNPs&Go) a neutral substitution is predicted
(reliability index 5 out of 10).
Table 3 Association results for advanced prostate cancer (Gleason score C8 or disease stage CIII) as compared to control subjects for the three
highly correlated SNPs and rs2735839
dbSNP rs
number
Position Alleles
a MAF
b Subjects v
2 P
c Allelic OR
(95% CI)
Genotype
ORHet (95% CI)
Genotype
ORHom (95% CI)
Control Case Control Case
rs62113212 56052652 C/T 0.072 0.085 3,325 674 1.02 0.312 1.12 (0.90–1.40) 1.17 (0.92–1.49) 0.72 (0.20–2.56)
rs17632542 56053569 T/C 0.072 0.081 3,325 671 0.31 0.578 1.07 (0.85–1.34) 1.13 (0.89–1.43) 0.48 (0.11–2.17)
rs62113214 56054349 T/G 0.072 0.084 3,321 676 0.69 0.407 1.10 (0.88–1.37) 1.14 (0.90–1.45) 0.73 (0.21–2.60)
rs2735839 56056435 G/A 0.136 0.154 2,980 603 2.10 0.148 1.15 (0.95–1.38) 1.16 (0.94–1.43) 1.22 (0.61–2.44)
OR odds ratio, Het heterozygous, Hom homozygous for minor allele, CI 95% conﬁdence interval. Coordinates are based on NCBI genome build
36.3. Results for aggressive prostate cancer as determined by a Gleason score C7 or disease stage of CIII are shown in supplemental Table 5
a Major allele/minor allele
b Minor allele frequency
c 1 df score test
Table 2 Association results for nonaggressive prostate cancer (Gleason score\7 and disease stage\III) as compared to control subjects for the
three highly correlated SNPs and rs2735839
dbSNP rs
number
Position Alleles
a MAF
b Subjects v
2 P
c Allelic OR
(95% CI)
Genotype
ORHet (95% CI)
Genotype
ORHom (95% CI)
Control Case Control Case
rs62113212 56052652 C/T 0.072 0.053 3,325 1,652 16.19 5.74 9 10
-05 0.69 (0.57–0.82) 0.70 (0.58–0.85) 0.33 (0.11–0.99)
rs17632542 56053569 T/C 0.072 0.054 3,325 1,652 16.27 5.49 9 10
-05 0.69 (0.57–0.82) 0.70 (0.57–0.85) 0.35 (0.11–1.05)
rs62113214 56054349 T/G 0.072 0.054 3,321 1,644 16.56 4.72 9 10
-05 0.68 (0.57–0.82) 0.70 (0.57–0.85) 0.34 (0.11–1.04)
rs2735839 56056435 G/A 0.136 0.122 2,980 1,422 4.65 0.031 0.85 (0.74–0.99) 0.85 (0.72–1.00) 0.76 (0.44–1.29)
OR odds ratio, Het heterozygous, Hom homozygous for minor allele, CI 95% conﬁdence interval. Coordinates are based on NCBI genome build
36.3
a Major allele/minor allele
b Minor allele frequency
c 1 df score test
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123Discussion
Here we describe a comprehensive ﬁne mapping effort in
the KLK3 gene based on resequence data across a region of
chr19q13.33, surrounding rs2735839, a SNP previously
associated with prostate cancer (Eeles et al. 2008; Kote-
Jarai et al. 2008) and/or serum prostate-speciﬁc antigen
(PSA) levels (Ahn et al. 2008). Based on a comprehensive
catalog of common variation in a 56 kb region surrounding
KLK3 by deep resequencing (Parikh et al. 2010) we now
report the follow-up genotyping of tag SNPs in close to
7,000 subjects drawn from ﬁve prostate cancer studies. We
did not observe signiﬁcant association between rs2735839
and overall prostate cancer risk. However, three highly
correlated, neighboring SNPs in KLK3 were associated
with overall prostate cancer risk. This signal was detected
only in association with nonaggressive prostate cancer and
was not present in men with advanced prostate cancer. The
signiﬁcance level for these three SNPs is modest and did
not reach the threshold for genome-wide signiﬁcance in
GWAS (2007). Nevertheless, our ﬁndings suggest that
these three SNPs are associated with either developing or
being diagnosed with nonaggressive prostate cancer,
potentially due to differential case identiﬁcation related to
PSA level. Two of the SNPs are intronic but the third
causes a non-synonymous amino acid substitution in the
Table 4 Association between the three highly correlated SNPs as well as rs2735839 and baseline PSA levels in the PLCO cohort
dbSNP rs number Position Alleles
b Means
a General linear model (adjusted)
G = 0
c G = 1
d
n Mean n Mean b Reduction
e P
(95% CI) (95% CI)
Controls
rs62113212 56052652 C/T 584 1.61 (1.49–1.72) 108 1.12 (0.96–1.28) -0.36 0.30 9.70 9 10
-05
rs17632542 56053569 T/C 582 1.61 (1.49–1.72) 107 1.13 (0.97–1.29) -0.35 0.30 1.50 9 10
-04
rs62113214 56054349 T/G 583 1.60 (1.49–1.72) 107 1.14 (0.98–1.30) -0.34 0.29 2.40 9 10
-04
rs2735839 56056435 G/A 491 1.64 (1.51–1.77) 199 1.28 (1.12–1.44) -0.25 0.22 1.00 9 10
-03
Cases
rs62113212 56052652 C/T 387 4.35 (3.83–4.86) 51 3.46 (3.01–3.91) -0.19 0.17 0.12
rs17632542 56053569 T/C 386 4.35 (3.84–4.86) 48 3.57 (3.13–4.01) -0.16 0.15 0.20
rs62113214 56054349 T/G 387 4.34 (3.83–4.85) 50 3.48 (3.03–3.94) -0.19 0.17 0.13
rs2735839 56056435 G/A 325 4.24 (3.73–4.76) 112 3.92 (3.19–4.64) -0.10 0.10 0.23
Coordinates are based on NCBI genome build 36.3
bb -coefﬁcient, CI 95% conﬁdence interval
a Baseline PSA levels are shown in ng/ml
b Major allele/minor allele
c G = 0, individuals without a minor allele
d G = 1, individuals with at least one minor allele
e Reduction, % reduction in G = 1 as compared to G = 0
G = 0 G = 1
0
2
1
3
4
5 P = 9.70 x 10
-05
G = 0 G = 1
0
2
1
3
4
5 P = 1.00 x 10
-03
AB
rs62113212 rs2735839
P
S
A
 
l
e
v
e
l
s
 
(
n
g
/
m
L
)
P
S
A
 
l
e
v
e
l
s
 
(
n
g
/
m
L
)
Fig. 2 Box plots showing PSA
levels (ng/ml) at baseline in
control subjects from the PLCO
study for carriers (G = 1) and
noncarriers (G = 0) of minor
alleles at rs62113212 (a) and
rs2735839 (b). Median values
are indicated by a horizontal
line and 25 and 75% are at the
bottom and top of the boxes
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123KLK3 protein albeit with minimal predicted shift in
function.
A recent report did not ﬁnd a signiﬁcant association
between SNPs in KLK genes and prostate cancer risk in a
Swedish population-based case–control study comprising
1,419 prostate cancer cases and 736 controls. This study
analyzed SNPs in coding and promoter regions of all 15
kallikrein genes and included both rs17632542 and
rs2735839 (but not rs62113212 or rs62113214) (Klein et al.
2010). We did not observe additional signals in KLK3 or in
the neighboring KLK2 and KLK15 genes by imputation.
We also observed that baseline PSA levels were lower in
control subjects carrying one or more minor alleles at the
three highly correlated SNPs. This may indicate that one or
more of these alleles directly cause a reduction in serum
PSA levels, possibly through regulatory effects (on tran-
scription of the gene), through altered protein stability or
reduced detection of serum PSA. However, since many
factors could play a role in regulating serum PSA levels
this question still remains open and requires validation and
further investigations. Reduced PSA levels were also noted
in carriers of minor alleles at rs2735839 although the effect
was less pronounced.
The implications of our study directly pertain to the
relationship between germline KLK3 variants, serum PSA
levels and detection of prostate cancer through PSA
screening. Since the introduction of the PSA test as a
screening tool in the US in the late 1980s, reported prostate
cancer incidence rates have risen sharply (Welch and Al-
bertsen 2009), especially for early stage disease and
younger individuals (Shao et al. 2009). A signiﬁcant num-
ber of men are likely to be ‘over-diagnosed’ as a result of
PSA screening, where patients with clinically insigniﬁcant
cancers that are unlikely to progress within their lifetime are
diagnosed and treated, often with grave adverse effects on
quality of life (Welch and Albertsen 2009). Two large
randomized screening trials are now ongoing to assess the
beneﬁts of the PSA test for prostate cancer screening and
reduction of mortality. Although interim results have been
published, it is not clear if the test reduces mortality from
prostate cancer (Andriole et al. 2009; Schroder et al. 2009).
We have ﬁne mapped a challenging association signal in
the KLK3 gene to three highly correlated SNPs centromeric
to the original signal reported by Eeles et al. (2008). Since
we observed that the same three SNPs were also signiﬁ-
cantly associated with baseline PSA levels in the prospec-
tive PLCO cohort, we interpret our results to suggest that
the effect may perhaps be a consequence of PSA screening
as well. It is possible that the KLK3 locus also contributes to
prostate cancer risk. Further studies are needed to dissect
the contribution of genetic variation in KLK3 to PSA levels
and prostate risk separately in an effort to elucidate the
possibility of pleotropic effects of the KLK3 locus.
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